Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/25055| Title: | Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter study. | Austin Authors: | Bhurani, Mansi;Admojo, Lorenz;Van Der Weyden, Carrie;Twigger, Robert;Bazargan, Ali;Quach, Hang;Zimet, Allan;Coyle, Luke;Lindsay, Julian;Radeski, Dejan;Hawkes, Eliza A ;Kennedy, Glen;Irving, Ian;Gutta, Naadir;Trotman, Judith;Yeung, James;Dunlop, Lindsay;Hua, Minh;Giri, Pratyush;Yuen, Sam;Panicker, Shyam;Moreton, Susan;Khoo, Liane;Scott, Ashleigh;Kipp, David;McQuillan, Andrew;McCormack, Chris;Dickinson, Michael;Prince, Henry Miles | Affiliation: | Royal Adelaide Hospital, Adelaide, SA, Australia Southern Highland Private Hospital, Liverpool, NSW, Australia Royal Prince Alfred Hospital, Sydney, NSW, Australia Concord Hospital, Sydney, NSW, Australia Icon Cancer Care, Brisbane, QLD, Australia Mater Cancer Care Centre, Brisbane, QLD, Australia Olivia Newton-John Cancer Research Institute Hollywood Medical Centre, Nedlands, WA, Australia Barwon Health Cancer Services, Geelong, VIC, Australia Hills Specialist Group, Bella Vista, NSW, Australia Calvary Mater, Newcastle, NSW, Australia St Vincent's Health, Melbourne, VIC, Australia Royal Brisbane and Women's Hospital, Herston, QLD, Australia Sir Peter MacCallum Department of Surgical Oncology, Parkville, VIC, Australia Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia Sir Charles Gairdner Hospital, Nedlands, WA, Australia Royal North Shore Hospital, Sydney, NSW, Australia Faculty of Medicine, Nursing, and Health Sciences, Monash University, Melbourne, VIC, Australia Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia Dubbo Base Hospital, Dubbo, NSW, Australia Epworth Healthcare, Melbourne, VIC, Australia |
Issue Date: | Feb-2021 | Date: | 2020-10-07 | Publication information: | Leukemia & Lymphoma 2021; 62(2): 330-336 | Abstract: | We present a retrospective multicenter study of pralatrexate treatment outcomes in an Australian practice setting for patients with relapsed/refractory T-cell lymphoma who had failed 1+ systemic therapies, treated via a compassionate access program. Endpoints assessed included response rates, toxicities, and subsequent therapies. Progression-free survival (PFS), time to next treatment (TTNT), event-free survival (EFS), overall survival (OS), and time to best response, were assessed by Kaplan-Meier analysis. The study included 31 patients, with median age 69 years. We demonstrated ORR of 35.5% (n = 11), including 4 complete responses (13%) and 7 partial responses (23%). The predicted median OS was 10 months, with EFS of 9 months, and PFS of 9 months. Median TTNT was 8 months. Mucositis was the most commonly observed toxicity. This study - the second largest real-world cohort reported to date - underscores the importance of pralatrexate in relapsed/refractory T-cell lymphoma, as well as its acceptable toxicity profile. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/25055 | DOI: | 10.1080/10428194.2020.1827241 | ORCID: | 0000-0001-6566-6215 0000-0002-4796-3352 |
Journal: | Leukemia & Lymphoma | PubMed URL: | 33026266 | Type: | Journal Article | Subjects: | Pralatrexate T-cell lymphoma cutaneous T-cell lymphoma mucositis peripheral T-cell lymphoma |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.